In the African American Study of Kidney Disease and Hypertension (AASK) trial, it was revealed that for Black individuals with non-diabetic renal disease, ACE inhibitors were more effective at slowing the course than other antihypertensives [44]. The gene discussed is ACE; the disease is Hypertension.